Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win

An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.